1
|
Xu Q, Sharif M, James E, Dismorr JO, Tucker JHR, Willcox BE, Mehellou Y. Phosphonodiamidate prodrugs of phosphoantigens (ProPAgens) exhibit potent Vγ9/Vδ2 T cell activation and eradication of cancer cells. RSC Med Chem 2024; 15:2462-2473. [PMID: 39026632 PMCID: PMC11253855 DOI: 10.1039/d4md00208c] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2024] [Accepted: 05/30/2024] [Indexed: 07/20/2024] Open
Abstract
The phosphoantigen (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP) is an established activator of Vγ9/Vδ2 T cells and stimulates downstream effector functions including cytotoxicity and cytokine production. In order to improve its drug-like properties, we herein report the design, synthesis, serum stability, in vitro metabolism, and biological evaluation of a new class of symmetrical phosphonodiamidate prodrugs of methylene and difluoromethylene monophosphonate derivatives of HMBPP. These prodrugs, termed phosphonodiamidate ProPAgens, were synthesized in good yields, exhibited excellent serum stability (>7 h), and their in vitro metabolism was shown to be initiated by carboxypeptidase Y. These phosphonodiamidate ProPAgens triggered potent activation of Vγ9/Vδ2 T cells, which translated into efficient Vγ9/Vδ2 T cell-mediated eradication of bladder cancer cells in vitro. Together, these findings showcase the potential of these phosphonodiamidate ProPAgens as Vγ9/Vδ2 T cell modulators that could be further developed as novel cancer immunotherapeutic agents.
Collapse
Affiliation(s)
- Qin Xu
- School of Pharmacy and Pharmaceutical Sciences, Cardiff University Cardiff CF10 3NB UK
| | - Maria Sharif
- Institute of Immunology and Immunotherapy, University of Birmingham Birmingham B15 2TT UK
- Cancer Immunology and Immunotherapy Centre, University of Birmingham Birmingham B15 2TT UK
| | - Edward James
- School of Pharmacy and Pharmaceutical Sciences, Cardiff University Cardiff CF10 3NB UK
| | - Jack O Dismorr
- School of Chemistry, University of Birmingham Birmingham B15 2TT UK
| | - James H R Tucker
- School of Chemistry, University of Birmingham Birmingham B15 2TT UK
| | - Benjamin E Willcox
- Institute of Immunology and Immunotherapy, University of Birmingham Birmingham B15 2TT UK
- Cancer Immunology and Immunotherapy Centre, University of Birmingham Birmingham B15 2TT UK
| | - Youcef Mehellou
- School of Pharmacy and Pharmaceutical Sciences, Cardiff University Cardiff CF10 3NB UK
- Medicines Discovery Institute, Cardiff University Cardiff CF10 3AT UK
| |
Collapse
|
2
|
Said YA, Hammad SF, Halim MI, El-Moneim AA, Osman A. Assessment of the therapeutic potential of a novel phosphoramidate acyclic nucleoside on induced hepatocellular carcinoma in rat model. Life Sci 2024:122669. [PMID: 38677390 DOI: 10.1016/j.lfs.2024.122669] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2024] [Revised: 04/11/2024] [Accepted: 04/23/2024] [Indexed: 04/29/2024]
Abstract
AIMS Hepatocellular Carcinoma (HCC) is renowned as a deadly primary cancer of hepatic origin. Sorafenib is the drug-of-choice for targeted treatment of unresectable end-stage HCC. Unfortunately, great proportion of HCC patients showed intolerance or unresponsiveness to treatment. This study assesses potency of novel ProTide; SH-PAN-19 against N-Nitrosodiethylamine (DEN)-induced HCC in male Wistar rats, compared to Sorafenib. MAIN METHODS Structural entity of the synthesized compound was substantiated via FT-IR, UV-Vis, 1H NMR and 13C NMR spectroscopic analysis. In vitro, SH-PAN-19 cytotoxicity was tested against 3 human cell lines; hepatocellular carcinoma; HepG-2, colorectal carcinoma; HCT-116 and normal fibroblasts; MRC-5. In vivo, therapeutic efficacy of SH-PAN-19 (300 mg/kg b.w./day) against HCC could be revealed and compared to that of Sorafenib (15 mg/kg b.w./day) by evaluating the morphometric, biochemical, histopathological, immunohistochemical and molecular key markers. KEY FINDINGS SH-PAN-19 was relatively safe toward MRC-5 cells (IC50 = 307.6 μg/mL), highly cytotoxic to HepG-2 cells (IC50 = 24.9 μg/mL) and prominently hepato-selective (TSI = 12.35). Oral LD50 of SH-PAN-19 was >3000 mg/kg b.w. DEN-injected rats suffered hepatomegaly, oxidative stress, elevated liver enzymes, hypoalbuminemia, bilirubinemia and skyrocketed AFP plasma titre. SH-PAN-19 alleviated the DEN-induced alterations in apoptotic, angiogenic and inflammatory markers. SH-PAN-19 produced a 2.5-folds increase in Caspase-9 and downregulated VEGFR-2, IL-6, TNF-α, TGFβ-1, MMP-9 and CcnD-1 to levels comparable to that elicited by Sorafenib. SH-PAN-19 resulted in near-complete pathological response versus partial response achieved by Sorafenib. SIGNIFICANCE This research illustrated that SH-PAN-19 is a promising chemotherapeutic agent capable of restoring cellular plasticity and could stop HCC progression.
Collapse
Affiliation(s)
- Youssef A Said
- Biotechnology Program, Basic and Applied Sciences Institute, Egypt-Japan University of Science and Technology (E-JUST), 21934 New Borg El-Arab City, Alexandria, Egypt; Biochemistry Department, Faculty of Science, Ain Shams University, 11566 Cairo, Egypt.
| | - Sherif F Hammad
- Medicinal Chemistry Department, PharmD Program, Egypt-Japan University of Science and Technology (E-JUST), 21934 New Borg El-Arab City, Alexandria, Egypt; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Helwan University, 11795 Cairo, Egypt
| | - Mariam I Halim
- Pathology Department, Faculty of Medicine, Ain Shams University, 11566 Cairo, Egypt
| | - Ahmed Abd El-Moneim
- Graphene Center of Excellence, Egypt-Japan University of Science and Technology (E-JUST), 21934 New Borg El-Arab City, Alexandria, Egypt; Physical Chemistry Department, National Research Centre (NRC), 12622 Cairo, Egypt
| | - Ahmed Osman
- Biotechnology Program, Basic and Applied Sciences Institute, Egypt-Japan University of Science and Technology (E-JUST), 21934 New Borg El-Arab City, Alexandria, Egypt; Biochemistry Department, Faculty of Science, Ain Shams University, 11566 Cairo, Egypt
| |
Collapse
|
3
|
Humboldt A, Rami F, Topp FM, Arnold D, Göhringer D, Pallan PS, Egli M, Richert C. Prolinyl Phosphoramidates of Nucleotides with Increased Reactivity. Angew Chem Int Ed Engl 2024; 63:e202319958. [PMID: 38300702 DOI: 10.1002/anie.202319958] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2023] [Revised: 01/30/2024] [Accepted: 01/31/2024] [Indexed: 02/02/2024]
Abstract
Nucleoside monophosphates (NMPs) are the subunits of RNA. They are incorporated into growing complementary strands when sequences are copied in enzyme-free reactions using organic leaving groups at the phosphates. Amino acids are rarely considered as leaving groups, but proline can act as a leaving group when N-linked to NMPs, so that prolinyl NMPs hydrolyze in aqueous buffer at 37 °C, with half-life times as short as 2.4 h, and they act as monomers in enzyme-free primer extension. Still, their level of reactivity is insufficient for practical purposes, requiring months for some extensions. Herein we report the synthesis of eight substituted prolinyl AMPs together with seven related compounds and the results of a study of their reactivity. A δ-carboxy prolinyl NMP was found to be converted with a half-life time of just 11 min in magnesium-free buffer, and a δ-isopropyl prolinyl NMP was shown to react sevenfold faster than its prolinyl counterpart in enzyme-free genetic copying of RNA. Our results indicate that both anchimeric and steric effects can be employed to increase the reactivity of aminoacidyl nucleotides, i.e. compounds that combine two fundamental classes of biomolecules in one functional entity.
Collapse
Affiliation(s)
- Adrian Humboldt
- Institute of Organic Chemistry, University of Stuttgart, 70569, Stuttgart, Germany
| | - Fabian Rami
- Institute of Organic Chemistry, University of Stuttgart, 70569, Stuttgart, Germany
| | - Franka M Topp
- Institute of Organic Chemistry, University of Stuttgart, 70569, Stuttgart, Germany
| | - Dejana Arnold
- Institute of Organic Chemistry, University of Stuttgart, 70569, Stuttgart, Germany
| | - Daniela Göhringer
- Institute of Organic Chemistry, University of Stuttgart, 70569, Stuttgart, Germany
| | - Pradeep S Pallan
- Department of Biochemistry, Vanderbilt University, School of Medicine, Nashville, Tennessee, 37232, USA
| | - Martin Egli
- Department of Biochemistry, Vanderbilt University, School of Medicine, Nashville, Tennessee, 37232, USA
| | - Clemens Richert
- Institute of Organic Chemistry, University of Stuttgart, 70569, Stuttgart, Germany
| |
Collapse
|
4
|
Spiliopoulou P, Kazmi F, Aroldi F, Holmes T, Thompson D, Griffiths L, Qi C, Parkes M, Lord S, Veal GJ, Harrison DJ, Coyle VM, Graham J, Jeffry Evans TR, Blagden SP. A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301). J Exp Clin Cancer Res 2024; 43:100. [PMID: 38566164 PMCID: PMC10986017 DOI: 10.1186/s13046-024-03010-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2023] [Accepted: 03/11/2024] [Indexed: 04/04/2024] Open
Abstract
PURPOSE 5-fluorouracil (5-FU) is inefficiently converted to the active anti-cancer metabolite, fluorodeoxyuridine-monophosphate (FUDR-MP), is associated with dose-limiting toxicities and challenging administration schedules. NUC-3373 is a phosphoramidate nucleotide analog of fluorodeoxyuridine (FUDR) designed to overcome these limitations and replace fluoropyrimidines such as 5-FU. PATIENTS AND METHODS NUC-3373 was administered as monotherapy to patients with advanced solid tumors refractory to standard therapy via intravenous infusion either on Days 1, 8, 15 and 22 (Part 1) or on Days 1 and 15 (Part 2) of 28-day cycles until disease progression or unacceptable toxicity. Primary objectives were maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) and schedule of NUC-3373. Secondary objectives included pharmacokinetics (PK), and anti-tumor activity. RESULTS Fifty-nine patients received weekly NUC-3373 in 9 cohorts in Part 1 (n = 43) and 3 alternate-weekly dosing cohorts in Part 2 (n = 16). They had received a median of 3 prior lines of treatment (range: 0-11) and 74% were exposed to prior fluoropyrimidines. Four experienced dose-limiting toxicities: two Grade (G) 3 transaminitis; one G2 headache; and one G3 transient hypotension. Commonest treatment-related G3 adverse event of raised transaminases occurred in < 10% of patients. NUC-3373 showed a favorable PK profile, with dose-proportionality and a prolonged half-life compared to 5-FU. A best overall response of stable disease was observed, with prolonged progression-free survival. CONCLUSION NUC-3373 was well-tolerated in a heavily pre-treated solid tumor patient population, including those who had relapsed on prior 5-FU. The MTD and RP2D was defined as 2500 mg/m2 NUC-3373 weekly. NUC-3373 is currently in combination treatment studies. TRIAL REGISTRATION Clinicaltrials.gov registry number NCT02723240. Trial registered on 8th December 2015. https://clinicaltrials.gov/study/NCT02723240 .
Collapse
Affiliation(s)
- Pavlina Spiliopoulou
- School of Cancer Sciences, University of Glasgow, Glasgow, UK
- Beatson West of Scotland Cancer Centre, Glasgow, UK
| | - Farasat Kazmi
- Early Phase Clinical Trials Unit, Churchill Hospital, Oxford University Hospitals, Oxford, UK
| | - Francesca Aroldi
- Early Phase Clinical Trials Unit, Churchill Hospital, Oxford University Hospitals, Oxford, UK
| | - Thomas Holmes
- Department of Oncology, Oncology Clinical Trials Office, University of Oxford, Oxford, UK
| | - David Thompson
- Department of Oncology, Oncology Clinical Trials Office, University of Oxford, Oxford, UK
| | - Lucinda Griffiths
- Department of Oncology, Oncology Clinical Trials Office, University of Oxford, Oxford, UK
| | - Cathy Qi
- Centre for Statistics in Medicine and Oxford Clinical Trials Research Unit (OCTRU), Oxford, UK
| | - Matthew Parkes
- Centre for Statistics in Medicine and Oxford Clinical Trials Research Unit (OCTRU), Oxford, UK
| | - Simon Lord
- Early Phase Clinical Trials Unit, Churchill Hospital, Oxford University Hospitals, Oxford, UK
| | - Gareth J Veal
- Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Newcastle upon Tyne, UK
| | - David J Harrison
- School of Medicine, University of St Andrews, St Andrews, UK
- NuCana plc, 3 Lochside Way, Edinburgh, UK
| | - Vicky M Coyle
- Patrick G. Johnston Centre for Cancer Research, Queens University Belfast, Belfast, UK
| | - Jill Graham
- Beatson West of Scotland Cancer Centre, Glasgow, UK
| | - Thomas R Jeffry Evans
- School of Cancer Sciences, University of Glasgow, Glasgow, UK
- Beatson West of Scotland Cancer Centre, Glasgow, UK
| | - Sarah P Blagden
- Early Phase Clinical Trials Unit, Churchill Hospital, Oxford University Hospitals, Oxford, UK.
- Department of Oncology, Oncology Clinical Trials Office, University of Oxford, Oxford, UK.
- Department of Oncology, University of Oxford, Old Road Campus Research Building, Oxford, OX3 7DQ, UK.
| |
Collapse
|
5
|
Serpi M, di Ciano S, Pertusati F. Design, synthesis and biological evaluation of aryloxy thiophosphoramidate triesters of anticancer nucleoside analogues. Bioorg Med Chem 2024; 103:117696. [PMID: 38547648 DOI: 10.1016/j.bmc.2024.117696] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2024] [Revised: 03/09/2024] [Accepted: 03/20/2024] [Indexed: 04/05/2024]
Abstract
Aryloxy phosphoroamidate triesters, known as ProTides, are a class of prodrugs developed to enhance the physicochemical and pharmacological properties of therapeutic nucleosides. This approach has been extensively investigated in the antiviral and anticancer areas leading to three prodrugs on the market and several others in clinical stage. In this article we have prepared the PS analogues of three ProTides that have reached the clinic as anticancer agents. These novel PS ProTides were tested for their capacity in enzymatic activation and for their cytotoxic properties against a panel of solid and liquid tumor cell lines. As expected, the replacement of the PO with a PS bond led to increased metabolic stability albeit concomitant to a decrease in potency. Surprisingly, the intermediate formed after the first activation step of a thiophosphoramidate with carboxypeptidase Y is not the expected PS aminoacyl product but the corresponding PO aminoacyl compound.
Collapse
Affiliation(s)
- Michaela Serpi
- School of Chemistry, Cardiff University, Main Building, Park Place, CF10 3AT Cardiff, Wales, UK
| | - Samule di Ciano
- School of Pharmacy and Pharmaceutical Sciences, Redwood Building, King Edwards VII avenue, CF10 3NB Cardiff, Wales, UK
| | - Fabrizio Pertusati
- School of Pharmacy and Pharmaceutical Sciences, Redwood Building, King Edwards VII avenue, CF10 3NB Cardiff, Wales, UK.
| |
Collapse
|
6
|
Sen A, Karati D. An insight into thymidylate synthase inhibitor as anticancer agents: an explicative review. NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY 2024:10.1007/s00210-024-03020-y. [PMID: 38446215 DOI: 10.1007/s00210-024-03020-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/05/2024] [Accepted: 02/20/2024] [Indexed: 03/07/2024]
Abstract
Cancer, a widespread challenge to global health, remains a puzzle of intricate molecular dynamics. This review article delves into the mystery of cancer, with a keen focus on understanding the contributory role of thymidylate synthase (TS) in cancer. TS, a vital enzyme in DNA synthesis and repair, emerges as a significant player in the narrative of cancer development. The conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP) is a major step in producing DNA. Numerous malignancies, including those of the breast, colon, lung, and ovary, have been linked to dysregulation of TS activity. Overexpression or mutations of TS lead to uncontrolled cell proliferation and tumorigenesis molecular interactions and signalling pathways involving TS come under scrutiny, revealing the nuanced connections that propel its involvement in cancer progression. Beyond overexpression and mutations, there emerges a subtle layer of regulation that involves microRNAs (miRNAs). These tiny particles attach to the TS messenger RNA, causing translational repression or its degradation, which in turn affects TS activity. Moving towards the therapeutic realm, thymidylate synthase inhibition acts as a promising anti-cancer strategy. Targeting TS with small-molecule inhibitors could provide a novel approach to treat various cancers. By reducing the number of available nucleotides, TS inhibition would slow down or halt cancer cell division, thus depriving the tumor of the building blocks required for its proliferation and growth. The aim is to assess the viability and effectiveness of targeting TS to halt or slow down cancer progression. There is growing evidence that, in comparison to traditional TS inhibitors, few novel antifolate TS inhibitors are effective against a wider variety of neoplasms, such as lung carcinomas. It has been discovered that TS inhibitors increase cancer tissues' sensitivity to chemotherapy and radiation, increasing their vulnerability to these treatments. This article aims to provide a comprehensive insight into TS, examining its cellular details, detailing the heterocyclic moieties and molecular foundations, and providing a promising future outlook.
Collapse
Affiliation(s)
- Aratrika Sen
- Department of Pharmaceutical Technology, School of Pharmacy, Techno India University, Kolkata, 700091, West Bengal, India
| | - Dipanjan Karati
- Department of Pharmaceutical Technology, School of Pharmacy, Techno India University, Kolkata, 700091, West Bengal, India.
| |
Collapse
|
7
|
Jiang L, Pan T, Lv Q, Yuan W, Liu X, Qu X, Luo D, Wan S, Cui S. Novel ProTide prodrugs of 5-fluoro-2'-deoxyuridine for the treatment of liver cancer. Eur J Med Chem 2023; 260:115763. [PMID: 37659196 DOI: 10.1016/j.ejmech.2023.115763] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2022] [Revised: 04/08/2023] [Accepted: 08/24/2023] [Indexed: 09/04/2023]
Abstract
ProTide prodrug technology has emerged as a promising way for the development of anti-viral and anti-tumor drugs, whereas, there are fewer applications for the treatment of liver cancer. Herein, a series of distinct 3'-ester ProTide prodrugs of 5-fluoro-2'-deoxyuridine (FdUR) were synthesized and evaluated for their anti-liver cancer activity. The most efficient prodrug 11b reached a sub-micromolar activity (IC50 = 0.42 ± 0.13 μM) against HepG2 and over 100-fold and 200-fold improvements compared to 5-FU, respectively. 11b also demonstrated favorable selectivity towards normal liver cells L-02 (IC50 > 100 μM). In vitro metabolic stability studies revealed that 11b is stable in the plasma and could be activated rapidly in the liver, which supported that 11b is liver-targeted. Importantly, to more accurately evaluate the anti-HCC activity of 11b, the liver orthotopic model was built and 11b significantly suppressed tumor growth (TGI = 75.5%) at a dose of 60 mg/kg/2d in vivo without obvious toxicity. Overall, these promising results indicated that 11b could serve as a safe and effective prodrug of 5-FU nucleoside for liver cancer therapy.
Collapse
Affiliation(s)
- Leilei Jiang
- Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, 266071, China
| | - Ting Pan
- Beijing Key Laboratory of Environmental Toxicology, Department of Toxicology and Sanitary Chemistry, School of Public Health, Capital Medical University, Beijing, 100069, China
| | - Qin Lv
- Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, 266071, China
| | - Wenmin Yuan
- Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, 266071, China
| | - Xiaochun Liu
- Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, 266071, China
| | - Xianjun Qu
- Department of Pharmacology, School of Basic Medical Sciences, Capital Medical University, Beijing, 100069, China
| | - Dongdong Luo
- Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, 266071, China.
| | - Shengbiao Wan
- Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, 266071, China.
| | - Shuxiang Cui
- Beijing Key Laboratory of Environmental Toxicology, Department of Toxicology and Sanitary Chemistry, School of Public Health, Capital Medical University, Beijing, 100069, China.
| |
Collapse
|
8
|
Dasari M, Pelly SC, Geng J, Gold HB, Pribut N, Sharma SK, D’Erasmo MP, Bartsch PW, Sun C, Toti K, Arnold RS, Petros JA, Xu L, Jiang Y, Miller EJ, Liotta DC. Discovery of 5'-Substituted 5-Fluoro-2'-deoxyuridine Monophosphate Analogs: A Novel Class of Thymidylate Synthase Inhibitors. ACS Pharmacol Transl Sci 2023; 6:702-709. [PMID: 37200809 PMCID: PMC10186355 DOI: 10.1021/acsptsci.2c00252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2022] [Indexed: 02/25/2023]
Abstract
5-Fluorouracil and 5-fluorouracil-based prodrugs have been used clinically for decades to treat cancer. Their anticancer effects are most prominently ascribed to inhibition of thymidylate synthase (TS) by metabolite 5-fluoro-2'-deoxyuridine 5'-monophosphate (FdUMP). However, 5-fluorouracil and FdUMP are subject to numerous unfavorable metabolic events that can drive undesired systemic toxicity. Our previous research on antiviral nucleotides suggested that substitution at the nucleoside 5'-carbon imposes conformational restrictions on the corresponding nucleoside monophosphates, rendering them poor substrates for productive intracellular conversion to viral polymerase-inhibiting triphosphate metabolites. Accordingly, we hypothesized that 5'-substituted analogs of FdUMP, which is uniquely active at the monophosphate stage, would inhibit TS while preventing undesirable metabolism. Free energy perturbation-derived relative binding energy calculations suggested that 5'(R)-CH3 and 5'(S)-CF3 FdUMP analogs would maintain TS potency. Herein, we report our computational design strategy, synthesis of 5'-substituted FdUMP analogs, and pharmacological assessment of TS inhibitory activity.
Collapse
Affiliation(s)
- Madhuri Dasari
- Department
of Chemistry, Emory University College of
Arts and Sciences, Atlanta, Georgia 30322, United States
| | - Stephen C. Pelly
- Department
of Chemistry, Emory University College of
Arts and Sciences, Atlanta, Georgia 30322, United States
| | - Jiafeng Geng
- Department
of Chemistry, Emory University College of
Arts and Sciences, Atlanta, Georgia 30322, United States
| | - Hannah B. Gold
- Department
of Chemistry, Emory University College of
Arts and Sciences, Atlanta, Georgia 30322, United States
| | - Nicole Pribut
- Department
of Chemistry, Emory University College of
Arts and Sciences, Atlanta, Georgia 30322, United States
| | - Savita K. Sharma
- Department
of Chemistry, Emory University College of
Arts and Sciences, Atlanta, Georgia 30322, United States
| | - Michael P. D’Erasmo
- Department
of Chemistry, Emory University College of
Arts and Sciences, Atlanta, Georgia 30322, United States
| | - Perry W. Bartsch
- Department
of Chemistry, Emory University College of
Arts and Sciences, Atlanta, Georgia 30322, United States
| | - Carrie Sun
- Department
of Urology, Emory University School of Medicine, Atlanta, Georgia 30322, United States
| | - Kiran Toti
- Department
of Chemistry, Emory University College of
Arts and Sciences, Atlanta, Georgia 30322, United States
| | - Rebecca S. Arnold
- Department
of Urology, Emory University School of Medicine, Atlanta, Georgia 30322, United States
- Winship
Cancer Institute, Emory University, Atlanta, Georgia 30322, United States
| | - John A. Petros
- Department
of Urology, Emory University School of Medicine, Atlanta, Georgia 30322, United States
- Winship
Cancer Institute, Emory University, Atlanta, Georgia 30322, United States
| | - Lingjie Xu
- Junrui
Biotechnology, Hangzhou, Zhejiang 310000, China
| | - Yi Jiang
- Junrui
Biotechnology, Hangzhou, Zhejiang 310000, China
| | - Eric J. Miller
- Winship
Cancer Institute, Emory University, Atlanta, Georgia 30322, United States
- Department
of Pharmacology and Chemical Biology, Emory
University School of Medicine, Atlanta, Georgia 30322, United States
| | - Dennis C. Liotta
- Department
of Chemistry, Emory University College of
Arts and Sciences, Atlanta, Georgia 30322, United States
- Winship
Cancer Institute, Emory University, Atlanta, Georgia 30322, United States
| |
Collapse
|
9
|
Bré J, Dickson AL, Read OJ, Zhang Y, McKissock FG, Mullen P, Tang P, Zickuhr GM, Czekster CM, Harrison DJ. The novel anti-cancer fluoropyrimidine NUC-3373 is a potent inhibitor of thymidylate synthase and an effective DNA-damaging agent. Cancer Chemother Pharmacol 2023; 91:401-412. [PMID: 37000221 PMCID: PMC10156769 DOI: 10.1007/s00280-023-04528-5] [Citation(s) in RCA: 10] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2022] [Accepted: 03/17/2023] [Indexed: 04/01/2023]
Abstract
INTRODUCTION Fluoropyrimidines, principally 5-fluorouracil (5-FU), remain a key component of chemotherapy regimens for multiple cancer types, in particular colorectal and other gastrointestinal malignancies. To overcome key limitations and pharmacologic challenges that hinder the clinical utility of 5-FU, NUC-3373, a phosphoramidate transformation of 5-fluorodeoxyuridine, was designed to improve the efficacy and safety profile as well as the administration challenges associated with 5-FU. METHODS Human colorectal cancer cell lines HCT116 and SW480 were treated with sub-IC50 doses of NUC-3373 or 5-FU. Intracellular activation was measured by LC-MS. Western blot was performed to determine binding of the active anti-cancer metabolite FdUMP to thymidylate synthase (TS) and DNA damage. RESULTS We demonstrated that NUC-3373 generates more FdUMP than 5-FU, resulting in a more potent inhibition of TS, DNA misincorporation and subsequent cell cycle arrest and DNA damage in vitro. Unlike 5-FU, the thymineless death induced by NUC-3373 was rescued by the concurrent addition of exogenous thymidine. 5-FU cytotoxicity, however, was only reversed by supplementation with uridine, a treatment used to reduce 5-FU-induced toxicities in the clinic. This is in line with our findings that 5-FU generates FUTP which is incorporated into RNA, a mechanism known to underlie the myelosuppression and gastrointestinal inflammation associated with 5-FU. CONCLUSION Taken together, these results highlight key differences between NUC-3373 and 5-FU that are driven by the anti-cancer metabolites generated. NUC-3373 is a potent inhibitor of TS that also causes DNA-directed damage. These data support the preliminary clinical evidence that suggest NUC-3373 has a favorable safety profile in patients.
Collapse
Affiliation(s)
- Jennifer Bré
- School of Medicine, University of St Andrews, North Haugh, St Andrews, KY16 9TF, UK.
- NuCana Plc, 3 Lochside Way, Edinburgh, EH12 9DT, UK.
| | - Alison L Dickson
- School of Medicine, University of St Andrews, North Haugh, St Andrews, KY16 9TF, UK
- NuCana Plc, 3 Lochside Way, Edinburgh, EH12 9DT, UK
| | - Oliver J Read
- School of Medicine, University of St Andrews, North Haugh, St Andrews, KY16 9TF, UK
- NuCana Plc, 3 Lochside Way, Edinburgh, EH12 9DT, UK
| | - Ying Zhang
- School of Medicine, University of St Andrews, North Haugh, St Andrews, KY16 9TF, UK
| | | | - Peter Mullen
- School of Medicine, University of St Andrews, North Haugh, St Andrews, KY16 9TF, UK
| | - Peijun Tang
- School of Biology, University of St Andrews, North Haugh, St Andrews, KY16 9ST, UK
| | - Greice M Zickuhr
- School of Biology, University of St Andrews, North Haugh, St Andrews, KY16 9ST, UK
| | - Clarissa M Czekster
- School of Biology, University of St Andrews, North Haugh, St Andrews, KY16 9ST, UK
| | - David J Harrison
- School of Medicine, University of St Andrews, North Haugh, St Andrews, KY16 9TF, UK
- NuCana Plc, 3 Lochside Way, Edinburgh, EH12 9DT, UK
| |
Collapse
|
10
|
Siekierska I, Lukaszewicz M, Worch R, Jankowska-Anyszka M, Piecyk K. Application of Phosphoramidate ProTide Technology for the Synthesis of 5'-mRNA Cap Analogs Modified on the Exocyclic Amine Group. ChemMedChem 2023; 18:e202200490. [PMID: 36658701 DOI: 10.1002/cmdc.202200490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2022] [Revised: 12/18/2022] [Indexed: 01/21/2023]
Abstract
Aryloxy triester phosphoramidate methodology, commonly known as ProTide technology, is one of the most widely used prodrug approaches applied to therapeutic nucleosides. This approach has been used extensively by the pharmaceutical industry and researchers in medicinal chemistry. Herein we report our adaptation of this effective method for the synthesis of bioactive 5'-mRNA cap analogues as inhibitors for targeting cap-dependent translation. The synthesis was performed in two main stages: preparation of N2-modified guanosine analogues and their subsequent transformation into prodrugs using phenylethoxy-l-alaninyl phosphorochloridate. The prepared pro-nucleotide cap analogues were tested for their capacity in enzymatic activation, inhibitory properties in a rabbit reticulocyte lysate system, and passive membrane translocation properties.
Collapse
Affiliation(s)
- Izabela Siekierska
- Faculty of Chemistry, University of Warsaw, 1 Pasteur St., 02-093, Warsaw, Poland
| | - Maciej Lukaszewicz
- Division of Biophysics, Institute of Experimental Physics, Faculty of Physics, University of Warsaw, 02-089, Warsaw, Poland
| | - Remigiusz Worch
- Nencki Institute of Experimental Biology, 3 Pasteur Street, 02-093, Warsaw, Poland
| | | | - Karolina Piecyk
- Faculty of Chemistry, University of Warsaw, 1 Pasteur St., 02-093, Warsaw, Poland
| |
Collapse
|
11
|
Xu X, Li Z, Yao X, Sun N, Chang J. Advanced prodrug strategies in nucleoside analogues targeting the treatment of gastrointestinal malignancies. Front Cell Dev Biol 2023; 11:1173432. [PMID: 37143892 PMCID: PMC10151537 DOI: 10.3389/fcell.2023.1173432] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2023] [Accepted: 04/07/2023] [Indexed: 05/06/2023] Open
Abstract
Gastrointestinal malignancies are common digestive system tumor worldwide. Nucleoside analogues have been widely used as anticancer drugs for the treatment of a variety of conditions, including gastrointestinal malignancies. However, low permeability, enzymatic deamination, inefficiently phosphorylation, the emergence of chemoresistance and some other issues have limited its efficacy. The prodrug strategies have been widely applied in drug design to improve pharmacokinetic properties and address safety and drug-resistance issues. This review will provide an overview of the recent developments of prodrug strategies in nucleoside analogues for the treatment of gastrointestinal malignancies.
Collapse
Affiliation(s)
| | | | | | - Nannan Sun
- *Correspondence: Nannan Sun, ; Junbiao Chang,
| | | |
Collapse
|
12
|
Serpi M, Ferrari V, McGuigan C, Ghazaly E, Pepper C. Synthesis and Characterization of NUC-7738, an Aryloxy Phosphoramidate of 3'-Deoxyadenosine, as a Potential Anticancer Agent. J Med Chem 2022; 65:15789-15804. [PMID: 36417756 PMCID: PMC9743095 DOI: 10.1021/acs.jmedchem.2c01348] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2022] [Indexed: 11/24/2022]
Abstract
3'-Deoxyadenosine (3'-dA, Cordycepin, 1) is a nucleoside analogue with anticancer properties, but its clinical development has been hampered due to its deactivation by adenosine deaminase (ADA) and poor cellular uptake due to low expression of the human equilibrative transporter (hENT1). Here, we describe the synthesis and characterization of NUC-7738 (7a), a 5'-aryloxy phosphoramidate prodrug of 3'-dA. We show in vitro evidence that 7a is an effective anticancer drug in a panel of solid and hematological cancer cell lines, showing its preferential cytotoxic effects on leukemic stem cells. We found that unlike 3'-dA, the activity of 7a was independent of hENT1 and kinase activity. Furthermore, it was resistant to ADA metabolic deactivation. Consistent with these findings, 7a showed increased levels of intracellular 3'-deoxyadenosine triphosphate (3'-dATP), the active metabolite. Mechanistically, levels of intracellular 3'-dATP were strongly associated with in vitro potency. NUC-7738 is now in Phase II, dose-escalation study in patients with advanced solid tumors.
Collapse
Affiliation(s)
- Michaela Serpi
- School
of Chemistry, Cardiff University Main Building, Park Place, Cardiff CF10 3AT, Wales, U.K.
| | - Valentina Ferrari
- School
of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, King Edward VII Avenue, Cardiff CF10 3NB, U.K.
| | - Christopher McGuigan
- School
of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, King Edward VII Avenue, Cardiff CF10 3NB, U.K.
| | - Essam Ghazaly
- Centre
for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, U.K.
| | - Chris Pepper
- Brighton
and Sussex Medical School, University of
Sussex, Brighton BN1 9PX, U.K.
| |
Collapse
|
13
|
Different phosphoric triamide [HN]3-nP(O)[N]n (n = 1, 2) skeletons lead to identical non-covalent interactions assemblies: X-ray crystallography investigation, Hirshfeld surface analysis and molecular docking study against SARS-CoV-2. Inorganica Chim Acta 2022. [DOI: 10.1016/j.ica.2022.121190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
14
|
Ford A, Mullins ND, Balzarini J, Maguire AR. Synthesis and Evaluation of Prodrugs of α-Carboxy Nucleoside Phosphonates. J Org Chem 2022; 87:14793-14808. [PMID: 36283025 PMCID: PMC9639015 DOI: 10.1021/acs.joc.2c02135] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
A range of lipophilic prodrugs of α-carboxy nucleoside phosphonates, potent inhibitors of HIV-1 reverse transcriptase without requiring prior phosphorylation, were synthesized to evaluate their in vivo potency against HIV in cell culture. A series of prodrug derivatives bearing a free carboxylic acid where the phosphonate was masked with bispivaloyloxymethyl, diisopropyloxycarbonyloxymethyl, bisamidate, aryloxyphosphoramidate, hexadecyloxypropyl, CycloSal, and acycloxybenzyl moieties were synthesized, adapting existing methodologies for phosphonate protection to accommodate the adjacent carboxylic acid moiety. The prodrugs were assayed for anti-HIV activity in CEM cell cultures─the bispivaloyloxymethyl free acid monophosphonate prodrug exhibited some activity (inhibitory concentration-50 (IC50) 59 ± 17 μM), while the other prodrugs were inactive at 100 μM. A racemic bispivaloyloxymethyl methyl ester monophosphonate prodrug was also prepared to assess the suitability of the methyl ester as a carboxylic acid prodrug. This compound exhibited no activity against HIV in cellular assays.
Collapse
Affiliation(s)
- Alan Ford
- School
of Chemistry, Analytical and Biological Chemistry Research Facility,
Synthesis and Solid State Pharmaceutical Centre, University College Cork, Cork T12 K8AF, Ireland
| | - Nicholas D. Mullins
- School
of Chemistry, Analytical and Biological Chemistry Research Facility,
Synthesis and Solid State Pharmaceutical Centre, University College Cork, Cork T12 K8AF, Ireland
| | - Jan Balzarini
- Rega
Institute for Medical Research, KU Leuven, Herestraat 49, B-3000 Leuven, Belgium
| | - Anita R. Maguire
- School
of Chemistry, Analytical and Biological Chemistry Research Facility,
Synthesis and Solid State Pharmaceutical Centre, University College Cork, Cork T12 K8AF, Ireland,School
of Pharmacy, Analytical and Biological Chemistry Research Facility,
Synthesis and Solid State Pharmaceutical Centre, University College Cork, Cork T12 K8AF, Ireland,
| |
Collapse
|
15
|
Krylov AS, Piterskaya YL, Gurzhiy VV, Voronina DY, Dogadina AV. Synthesis of Phosphoramidates Based on Aminopyridines. RUSS J GEN CHEM+ 2022. [DOI: 10.1134/s1070363222100061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
16
|
Alexandrova LA, Khandazhinskaya AL, Matyugina ES, Makarov DA, Kochetkov SN. Analogues of Pyrimidine Nucleosides as Mycobacteria Growth Inhibitors. Microorganisms 2022; 10:microorganisms10071299. [PMID: 35889017 PMCID: PMC9322969 DOI: 10.3390/microorganisms10071299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2022] [Revised: 06/23/2022] [Accepted: 06/24/2022] [Indexed: 01/25/2023] Open
Abstract
Tuberculosis (TB) is the oldest human infection disease. Mortality from TB significantly decreased in the 20th century, because of vaccination and the widespread use of antibiotics. However, about a third of the world’s population is currently infected with Mycobacterium tuberculosis (Mtb) and the death rate from TB is about 1.4–2 million people per year. In the second half of the 20th century, new extensively multidrug-resistant strains of Mtb were identified, which are steadily increasing among TB patients. Therefore, there is an urgent need to develop new anti-TB drugs, which remains one of the priorities of pharmacology and medicinal chemistry. The antimycobacterial activity of nucleoside derivatives and analogues was revealed not so long ago, and a lot of studies on their antibacterial properties have been published. Despite the fact that there are no clinically used drugs based on nucleoside analogues, some progress has been made in this area. This review summarizes current research in the field of the design and study of inhibitors of mycobacteria, primarily Mtb.
Collapse
|
17
|
García-Aranda MI, Franco-Pérez M, Bonilla-Landa I, Castrejón-Flores JL, Zamudio-Medina A. Synthesis of new aromatic phosphoramidates under a three-component reaction. PHOSPHORUS SULFUR 2022. [DOI: 10.1080/10426507.2022.2053854] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- Mónica I. García-Aranda
- Instituto Politécnico Nacional, Unidad Profesional Interdisciplinaria de Biotecnología, Mexico City, Mexico
| | - Marco Franco-Pérez
- Departamento de Física y Química Teórica, Facultad de Química, Universidad Nacional Autónoma de México, Ciudad Universitaria, México D.F, CP, México
| | - Israel Bonilla-Landa
- Red de Estudios Moleculares Avanzados CAMPUS III, Instituto de Ecología A.C. (INECOL), Xalapa-Enríquez, Veracruz, Mexico
| | - José Luis Castrejón-Flores
- Instituto Politécnico Nacional, Unidad Profesional Interdisciplinaria de Biotecnología, Mexico City, Mexico
| | - Angel Zamudio-Medina
- Instituto Politécnico Nacional, Unidad Profesional Interdisciplinaria de Biotecnología, Mexico City, Mexico
| |
Collapse
|
18
|
Wu F, Ni F, Yao J, Huang C, Zhao Y. Synthesis of Phosphoramidate Prodrugs of Phenolic Natural Products and Drugs by Ester Exchange. SYNTHESIS-STUTTGART 2022. [DOI: 10.1055/s-0041-1737911] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
AbstractDrug development based on phenolic natural products as drug candidates against various diseases has gained much attention in recent years. However, most of those molecules lack therapeutic efficacy in clinical trials, usually due to poor bioavailability. Therefore, a prodrug approach was adopted to address the bioavailability problem of phenolic drugs. This paper describes a mild and convenient method for late-stage ProTide-type prodrug synthesis of phenolic pharmaceuticals, which gives various phosphoramidate prodrugs from unprotected phenolic natural products and drugs in high yield. More importantly, this reaction is amenable for the selective phosphorylation of the phenolic hydroxyl group in the presence of otherwise problematic nucleophilic functional groups like amines and alcohols. We also observed that the chemical release rate of the phenol can be substantially tuned by changing the amino acid residue on the phosphoramidate moiety.
Collapse
Affiliation(s)
- Fan Wu
- Institute of Drug Discovery Technology, Ningbo University
- Qian Xuesen Collaborative Research Center of Astrochemistry and Space Life Sciences, Ningbo University
| | - Feng Ni
- Institute of Drug Discovery Technology, Ningbo University
- Qian Xuesen Collaborative Research Center of Astrochemistry and Space Life Sciences, Ningbo University
| | - Jie Yao
- Institute of Drug Discovery Technology, Ningbo University
- Qian Xuesen Collaborative Research Center of Astrochemistry and Space Life Sciences, Ningbo University
| | - Chengjie Huang
- Institute of Drug Discovery Technology, Ningbo University
- Qian Xuesen Collaborative Research Center of Astrochemistry and Space Life Sciences, Ningbo University
| | - Yufen Zhao
- Institute of Drug Discovery Technology, Ningbo University
- Qian Xuesen Collaborative Research Center of Astrochemistry and Space Life Sciences, Ningbo University
| |
Collapse
|
19
|
Schwenzer H, De Zan E, Elshani M, van Stiphout R, Kudsy M, Morris J, Ferrari V, Um IH, Chettle J, Kazmi F, Campo L, Easton A, Nijman S, Serpi M, Symeonides S, Plummer R, Harrison DJ, Bond G, Blagden SP. The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial. Clin Cancer Res 2021; 27:6500-6513. [PMID: 34497073 PMCID: PMC9401491 DOI: 10.1158/1078-0432.ccr-21-1652] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2021] [Revised: 07/04/2021] [Accepted: 09/02/2021] [Indexed: 01/07/2023]
Abstract
PURPOSE Nucleoside analogues form the backbone of many therapeutic regimens in oncology and require the presence of intracellular enzymes for their activation. A ProTide is comprised of a nucleoside fused to a protective phosphoramidate cap. ProTides are easily incorporated into cells whereupon the cap is cleaved and a preactivated nucleoside released. 3'-Deoxyadenosine (3'-dA) is a naturally occurring adenosine analogue with established anticancer activity in vitro but limited bioavailability due to its rapid in vivo deamination by the circulating enzyme adenosine deaminase, poor uptake into cells, and reliance on adenosine kinase for its activation. In order to overcome these limitations, 3'-dA was chemically modified to create the novel ProTide NUC-7738. EXPERIMENTAL DESIGN We describe the synthesis of NUC-7738. We determine the IC50 of NUC-7738 using pharmacokinetics (PK) and conduct genome-wide analyses to identify its mechanism of action using different cancer model systems. We validate these findings in patients with cancer. RESULTS We show that NUC-7738 overcomes the cancer resistance mechanisms that limit the activity of 3'-dA and that its activation is dependent on ProTide cleavage by the enzyme histidine triad nucleotide-binding protein 1. PK and tumor samples obtained from the ongoing first-in-human phase I clinical trial of NUC-7738 further validate our in vitro findings and show NUC-7738 is an effective proapoptotic agent in cancer cells with effects on the NF-κB pathway. CONCLUSIONS Our study provides proof that NUC-7738 overcomes cellular resistance mechanisms and supports its further clinical evaluation as a novel cancer treatment within the growing pantheon of anticancer ProTides.
Collapse
Affiliation(s)
- Hagen Schwenzer
- Department of Oncology, Medical Sciences Division, University of Oxford, Oxford, United Kingdom
- Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
| | - Erica De Zan
- Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
- Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
| | - Mustafa Elshani
- School of Medicine, University of St Andrews, St. Andrews, United Kingdom
| | - Ruud van Stiphout
- Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
- Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
| | - Mary Kudsy
- School of Medicine, University of St Andrews, St. Andrews, United Kingdom
| | - Josephine Morris
- Department of Oncology, Medical Sciences Division, University of Oxford, Oxford, United Kingdom
| | - Valentina Ferrari
- School of Pharmacy and Pharmaceutical Sciences, University of Cardiff, Cardiff, United Kingdom
| | - In Hwa Um
- School of Medicine, University of St Andrews, St. Andrews, United Kingdom
| | - James Chettle
- Department of Oncology, Medical Sciences Division, University of Oxford, Oxford, United Kingdom
| | - Farasat Kazmi
- Department of Oncology, Medical Sciences Division, University of Oxford, Oxford, United Kingdom
| | - Leticia Campo
- Department of Oncology, Medical Sciences Division, University of Oxford, Oxford, United Kingdom
| | - Alistair Easton
- Department of Oncology, Medical Sciences Division, University of Oxford, Oxford, United Kingdom
| | - Sebastian Nijman
- Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
- Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
| | - Michaela Serpi
- School of Pharmacy and Pharmaceutical Sciences, University of Cardiff, Cardiff, United Kingdom
| | - Stefan Symeonides
- Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, The University of Edinburgh, Western General Hospital, Edinburgh, United Kingdom
| | - Ruth Plummer
- Northern Centre for Cancer Care, Newcastle Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, United Kingdom
| | - David J Harrison
- School of Medicine, University of St Andrews, St. Andrews, United Kingdom
- NuCana PLC, Edinburgh, United Kingdom
| | - Gareth Bond
- Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
| | - Sarah P Blagden
- Department of Oncology, Medical Sciences Division, University of Oxford, Oxford, United Kingdom.
| |
Collapse
|
20
|
Alanazi AS, Miccoli A, Mehellou Y. Aryloxy Pivaloyloxymethyl Prodrugs as Nucleoside Monophosphate Prodrugs. J Med Chem 2021; 64:16703-16710. [PMID: 34734726 DOI: 10.1021/acs.jmedchem.1c01490] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Intracellular phosphorylation of therapeutic nucleoside analogues into their active triphosphate metabolites is a prerequisite for their pharmacological activity. However, the initial phosphorylation of these unnatural nucleosides into their monophosphate derivatives can be a rate-limiting step in their activation. To address this, we herein report the development of the aryloxy pivaloyloxymethyl prodrugs (POMtides) as a novel and effective nucleoside monophosphate prodrug technology and its successful application to the anticancer nucleoside analogue 5-fluoro-2'-deoxyuridine (FdUR).
Collapse
Affiliation(s)
- Ashwag S Alanazi
- School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Redwood Building, Cardiff CF10 3NB, U.K
| | - Ageo Miccoli
- School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Redwood Building, Cardiff CF10 3NB, U.K
| | - Youcef Mehellou
- School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Redwood Building, Cardiff CF10 3NB, U.K
| |
Collapse
|
21
|
Slusarczyk M, Serpi M, Ghazaly E, Kariuki BM, McGuigan C, Pepper C. Single Diastereomers of the Clinical Anticancer ProTide Agents NUC-1031 and NUC-3373 Preferentially Target Cancer Stem Cells In Vitro. J Med Chem 2021; 64:8179-8193. [PMID: 34085825 DOI: 10.1021/acs.jmedchem.0c02194] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
A 3'-protected route toward the synthesis of the diastereomers of clinically active ProTides, NUC-1031 and NUC-3373, is described. The in vitro cytotoxic activities of the individual diastereomers were found to be similar to their diastereomeric mixtures. In the KG1a cell line, NUC-1031 and NUC-3373 have preferential cytotoxic effects on leukemic stem cells (LSCs). These effects were not diastereomer-specific and were not observed with the parental nucleoside analogues gemcitabine and FUDR, respectively. In addition, NUC-1031 preferentially targeted LSCs in primary AML samples and cancer stem cells in the prostate cancer cell line, LNCaP. Although the mechanism for this remains incompletely resolved, NUC-1031-treated cells showed increased levels of triphosphate in both LSC and bulk tumor fractions. As ProTides are not dependent on nucleoside transporters, it seems possible that the LSC targeting observed with ProTides may be caused, at least in part, by preferential accumulation of metabolized nucleos(t)ide analogues.
Collapse
Affiliation(s)
- Magdalena Slusarczyk
- Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Redwood Building, Cardiff CF10 3NB, U.K
| | - Michaela Serpi
- Cardiff University, School of Chemistry, Main Building, Park Place, Cardiff CF10 3AT, U.K
| | - Essam Ghazaly
- Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, U.K
| | - Benson M Kariuki
- Cardiff University, School of Chemistry, Main Building, Park Place, Cardiff CF10 3AT, U.K
| | - Christopher McGuigan
- Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Redwood Building, Cardiff CF10 3NB, U.K
| | - Chris Pepper
- Brighton and Sussex Medical School, University of Sussex, Medical Teaching Building, Brighton BN1 9PX, U.K
| |
Collapse
|
22
|
Mechi H, Sanhoury M, Laribi F, Dhia MTB. Synthesis and characterization of new bis(fluoroalkyl) phosphoramidates bearing sulfoximine groups. J Sulphur Chem 2021. [DOI: 10.1080/17415993.2021.1931213] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- Hanen Mechi
- Laboratory of Structural Organic Chemistry: Synthesis and Physico-chemical Studies, Department of Chemistry. Faculty of Sciences of Tunis, University of Tunis El-Manar, Tunis, Tunisia
| | - M.A.K. Sanhoury
- Laboratory of Structural Organic Chemistry: Synthesis and Physico-chemical Studies, Department of Chemistry. Faculty of Sciences of Tunis, University of Tunis El-Manar, Tunis, Tunisia
- Department of Chemistry. Faculty of Sciences and Techniques, Materials Chemistry Research Unit, UNA, Nouakchott, Mauritania
| | - F. Laribi
- Laboratory of Structural Organic Chemistry: Synthesis and Physico-chemical Studies, Department of Chemistry. Faculty of Sciences of Tunis, University of Tunis El-Manar, Tunis, Tunisia
| | - M. T. Ben Dhia
- Laboratory of Structural Organic Chemistry: Synthesis and Physico-chemical Studies, Department of Chemistry. Faculty of Sciences of Tunis, University of Tunis El-Manar, Tunis, Tunisia
| |
Collapse
|
23
|
Serpi M, Pertusati F. An overview of ProTide technology and its implications to drug discovery. Expert Opin Drug Discov 2021; 16:1149-1161. [PMID: 33985395 DOI: 10.1080/17460441.2021.1922385] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Introduction: The ProTide technology is a phosphate (or phosphonate) prodrug method devised to deliver nucleoside monophosphate (or monophosphonate) intracellularly bypassing the key challenges of antiviral and anticancer nucleoside analogs. Three new antiviral drugs, exploiting this technology, have been approved by the FDA while others are in clinical studies as anticancer agents.Areas covered: The authors describe the origin and development of this technology and its incredible success in transforming the drug discovery of antiviral and anticancer nucleoside analogues. As evidence, discussion on the antiviral ProTides on the market, and those currently in clinical development are included. The authors focus on how the proven capacity of this technology to generate new drug candidates has stimulated its application to non-nucleoside-based molecules.Expert opinion: The ProTide approach has been extremely successful in delivering blockbuster antiviral medicines and it seems highly promising in oncology. Its application to non-nucleoside-based small molecules is recently emerging and proving effective in other therapeutic areas. However, investigations to explain the lack of activity of certain ProTide series and comprehensive structure activity relationship studies to identify the appropriate phosphoramidate motifs depending on the parent molecule are in our opinion mandatory for the future development of these compounds.
Collapse
Affiliation(s)
| | - Fabrizio Pertusati
- School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, UK
| |
Collapse
|
24
|
Yan VC, Pham CD, Arthur K, Yang KL, Muller FL. Aliphatic amines are viable pro-drug moieties in phosphonoamidate drugs. Bioorg Med Chem Lett 2020; 30:127656. [PMID: 33130289 DOI: 10.1016/j.bmcl.2020.127656] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2020] [Revised: 10/21/2020] [Accepted: 10/25/2020] [Indexed: 11/18/2022]
Abstract
Phosphate and phosphonates containing a single PN bond are frequently used pro-drug motifs to improve cell permeability of these otherwise anionic moieties. Upon entry into the cell, the PN bond is cleaved by phosphoramidases to release the active agent. Here, we apply a novel mono-amidation strategy to our laboratory's phosphonate-containing glycolysis inhibitor and show that a diverse panel of phosphonoamidates may be rapidly generated for in vitro screening. We show that, in contrast to the canonical l-alanine or benzylamine moieties which have previously been reported as efficacious pro-drug moieties, small and long-chain aliphatic amines demonstrate greater drug release efficacy for our phosphonate inhibitor. These results expand the scope of possible amine pro-drugs that can be used as second pro-drug leave groups for phosphate or phosphonate-containing drugs.
Collapse
Affiliation(s)
- Victoria C Yan
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA
| | - Cong-Dat Pham
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
| | - Kenisha Arthur
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA
| | - Kristine L Yang
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA
| | - Florian L Muller
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA
| |
Collapse
|
25
|
Jovanovic D, Tremmel P, Pallan PS, Egli M, Richert C. The Enzyme‐Free Release of Nucleotides from Phosphoramidates Depends Strongly on the Amino Acid. Angew Chem Int Ed Engl 2020. [DOI: 10.1002/ange.202008665] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Affiliation(s)
- Dejana Jovanovic
- Institut für Organische Chemie Universität Stuttgart 70569 Stuttgart Germany
| | - Peter Tremmel
- Institut für Organische Chemie Universität Stuttgart 70569 Stuttgart Germany
| | - Pradeep S. Pallan
- Department of Biochemistry Vanderbilt University School of Medicine Nashville TN 37232 USA
| | - Martin Egli
- Department of Biochemistry Vanderbilt University School of Medicine Nashville TN 37232 USA
| | - Clemens Richert
- Institut für Organische Chemie Universität Stuttgart 70569 Stuttgart Germany
| |
Collapse
|
26
|
Yan VC, Butterfield HE, Poral AH, Yan MJ, Yang KL, Pham CD, Muller FL. Why Great Mitotic Inhibitors Make Poor Cancer Drugs. Trends Cancer 2020; 6:924-941. [PMID: 32536592 PMCID: PMC7606322 DOI: 10.1016/j.trecan.2020.05.010] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2020] [Revised: 05/12/2020] [Accepted: 05/19/2020] [Indexed: 12/13/2022]
Abstract
Chemotherapy is central to oncology, perceived to operate only on prolific cancerous tissue. Yet, many non-neoplastic tissues are more prolific compared with typical tumors. Chemotherapies achieve sufficient therapeutic windows to exert antineoplastic activity because they are prodrugs that are bioactivated in cancer-specific environments. The advent of precision medicine has obscured this concept, favoring the development of high-potency kinase inhibitors. Inhibitors of essential mitotic kinases exemplify this paradigm shift, but intolerable on-target toxicities in more prolific normal tissues have led to repeated failures in the clinic. Proliferation rates alone cannot be used to achieve cancer specificity. Here, we discuss integrating the cancer specificity of prodrugs from classical chemotherapeutics and the potency of mitotic kinase inhibitors to generate a class of high-precision cancer therapeutics.
Collapse
Affiliation(s)
- Victoria C Yan
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
| | | | - Anton H Poral
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA
| | - Matthew J Yan
- Department of Chemistry, Boston College, Chestnut Hill, MA 02467, USA
| | - Kristine L Yang
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA
| | - Cong-Dat Pham
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA
| | - Florian L Muller
- Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
| |
Collapse
|
27
|
Smolobochkin AV, Turmanov RA, Abdullaeva DS, Gazizov AS, Voronina JK, Appazov NO, Buzyurova DN, Burilov AR, Pudovik MA. 2‐(Het)aryl‐
N
‐phosphorylpyrrolidines via Cyclization of Phosphorus Acid Amides: A Regioselective Approach. ChemistrySelect 2020. [DOI: 10.1002/slct.202003353] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- Andrey V. Smolobochkin
- Arbuzov Institute of Organic and Physical Chemistry FRC Kazan Scientific Center Russian Academy of Sciences, 4 20088 Arbuzova str., 8 Kazan Russian Federation
| | - Rakhymzhan A. Turmanov
- Arbuzov Institute of Organic and Physical Chemistry FRC Kazan Scientific Center Russian Academy of Sciences, 4 20088 Arbuzova str., 8 Kazan Russian Federation
- Kazan National Research Technological University 420015 Karl Marx str., 68 Kazan Russian Federation
| | | | - Almir S. Gazizov
- Arbuzov Institute of Organic and Physical Chemistry FRC Kazan Scientific Center Russian Academy of Sciences, 4 20088 Arbuzova str., 8 Kazan Russian Federation
| | - Julia K. Voronina
- N.S. Kurnakov Institute of General and Inorganic Chemistry, RAS 31 Leninsky Av. 119991 Moscow Russian Federation
- G.V. Plekhanov Russian University of Economics 36 Stremyanny Per. Moscow 117997 Russian Federation
| | - Nurbol O. Appazov
- Korkyt Ata Kyzylorda State University 120014 Aiteke bike str., 29A Kyzylorda, Republic of Kazakhstan
| | - Daina N. Buzyurova
- Arbuzov Institute of Organic and Physical Chemistry FRC Kazan Scientific Center Russian Academy of Sciences, 4 20088 Arbuzova str., 8 Kazan Russian Federation
| | - Alexander R. Burilov
- Arbuzov Institute of Organic and Physical Chemistry FRC Kazan Scientific Center Russian Academy of Sciences, 4 20088 Arbuzova str., 8 Kazan Russian Federation
| | - Michail A. Pudovik
- Arbuzov Institute of Organic and Physical Chemistry FRC Kazan Scientific Center Russian Academy of Sciences, 4 20088 Arbuzova str., 8 Kazan Russian Federation
| |
Collapse
|
28
|
Kadri H, Taher TE, Xu Q, Sharif M, Ashby E, Bryan RT, Willcox BE, Mehellou Y. Aryloxy Diester Phosphonamidate Prodrugs of Phosphoantigens (ProPAgens) as Potent Activators of Vγ9/Vδ2 T-Cell Immune Responses. J Med Chem 2020; 63:11258-11270. [PMID: 32930595 PMCID: PMC7549095 DOI: 10.1021/acs.jmedchem.0c01232] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Vγ9/Vδ2 T-cells are activated by pyrophosphate-containing small molecules known as phosphoantigens (PAgs). The presence of the pyrophosphate group in these PAgs has limited their drug-like properties because of its instability and polar nature. In this work, we report a novel and short Grubbs olefin metathesis-mediated synthesis of methylene and difluoromethylene monophosphonate derivatives of the PAg (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBP) as well as their aryloxy diester phosphonamidate prodrugs, termed ProPAgens. These prodrugs showed excellent stability in human serum (t1/2 > 12 h) and potent activation of Vγ9/Vδ2 T-cells (EC50 ranging from 5 fM to 73 nM), which translated into sub-nanomolar γδ T-cell-mediated eradication of bladder cancer cells in vitro. Additionally, a combination of in silico and in vitro enzymatic assays demonstrated the metabolism of these phosphonamidates to release the unmasked PAg monophosphonate species. Collectively, this work establishes HMBP monophosphonate ProPAgens as ideal candidates for further investigation as novel cancer immunotherapeutic agents.
Collapse
Affiliation(s)
- Hachemi Kadri
- School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff CF10 3NB, U.K
| | - Taher E Taher
- Cancer Immunology and Immunotherapy Centre, University of Birmingham, Edgbaston, Birmingham B15 2TT, U.K.,Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, Birmingham B15 2TT, U.K
| | - Qin Xu
- School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff CF10 3NB, U.K
| | - Maria Sharif
- Cancer Immunology and Immunotherapy Centre, University of Birmingham, Edgbaston, Birmingham B15 2TT, U.K.,Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, Birmingham B15 2TT, U.K
| | - Elizabeth Ashby
- Cancer Immunology and Immunotherapy Centre, University of Birmingham, Edgbaston, Birmingham B15 2TT, U.K.,Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, Birmingham B15 2TT, U.K
| | - Richard T Bryan
- Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, U.K
| | - Benjamin E Willcox
- Cancer Immunology and Immunotherapy Centre, University of Birmingham, Edgbaston, Birmingham B15 2TT, U.K.,Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, Birmingham B15 2TT, U.K
| | - Youcef Mehellou
- School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff CF10 3NB, U.K
| |
Collapse
|
29
|
Jovanovic D, Tremmel P, Pallan PS, Egli M, Richert C. The Enzyme-Free Release of Nucleotides from Phosphoramidates Depends Strongly on the Amino Acid. Angew Chem Int Ed Engl 2020; 59:20154-20160. [PMID: 32757352 PMCID: PMC7436718 DOI: 10.1002/anie.202008665] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2020] [Revised: 08/04/2020] [Indexed: 12/23/2022]
Abstract
Phosphoramidates composed of an amino acid and a nucleotide analogue are critical metabolites of prodrugs, such as remdesivir. Hydrolysis of the phosphoramidate liberates the nucleotide, which can then be phosphorylated to become the pharmacologically active triphosphate. Enzymatic hydrolysis has been demonstrated, but a spontaneous chemical process may also occur. We measured the rate of enzyme-free hydrolysis for 17 phosphoramidates of ribonucleotides with amino acids or related compounds at pH 7.5. Phosphoramidates of proline hydrolyzed fast, with a half-life time as short as 2.4 h for Pro-AMP in ethylimidazole-containing buffer at 37 °C; 45-fold faster than Ala-AMP and 120-fold faster than Phe-AMP. Crystal structures of Gly-AMP, Pro-AMP, βPro-AMP and Phe-AMP bound to RNase A as crystallization chaperone showed how well the carboxylate is poised to attack the phosphoramidate, helping to explain this reactivity. Our results are significant for the design of new antiviral prodrugs.
Collapse
Affiliation(s)
- Dejana Jovanovic
- Institut für Organische Chemie, Universität Stuttgart, 70569, Stuttgart, Germany
| | - Peter Tremmel
- Institut für Organische Chemie, Universität Stuttgart, 70569, Stuttgart, Germany
| | - Pradeep S Pallan
- Department of Biochemistry, Vanderbilt University, School of Medicine, Nashville, TN, 37232, USA
| | - Martin Egli
- Department of Biochemistry, Vanderbilt University, School of Medicine, Nashville, TN, 37232, USA
| | - Clemens Richert
- Institut für Organische Chemie, Universität Stuttgart, 70569, Stuttgart, Germany
| |
Collapse
|
30
|
Sun Y, Ke Y, Li C, Wang J, Tu L, Hu L, Jin Y, Chen H, Gong J, Yu Z. Bifunctional and Unusual Amino Acid β- or γ-Ester Prodrugs of Nucleoside Analogues for Improved Affinity to ATB0,+ and Enhanced Metabolic Stability: An Application to Floxuridine. J Med Chem 2020; 63:10816-10828. [DOI: 10.1021/acs.jmedchem.0c00149] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- Yongbing Sun
- Division of Pharmaceutics, Jiangxi University of Traditional Chinese Medicine, No. 1688 Meiling Road, Nanchang 330004, China
| | - Yu Ke
- Division of Pharmaceutics, Jiangxi University of Traditional Chinese Medicine, No. 1688 Meiling Road, Nanchang 330004, China
| | - Chunshi Li
- Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, No. 103 Wenhua Road, Shenyang 110016, China
| | - Jian Wang
- Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, No. 103 Wenhua Road, Shenyang 110016, China
| | - Liangxing Tu
- Division of Pharmaceutics, Jiangxi University of Traditional Chinese Medicine, No. 1688 Meiling Road, Nanchang 330004, China
| | - Lvjiang Hu
- Division of Pharmaceutics, Jiangxi University of Traditional Chinese Medicine, No. 1688 Meiling Road, Nanchang 330004, China
| | - Yi Jin
- Division of Pharmaceutics, Jiangxi University of Traditional Chinese Medicine, No. 1688 Meiling Road, Nanchang 330004, China
| | - Hao Chen
- Division of Pharmaceutics, Jiangxi University of Traditional Chinese Medicine, No. 1688 Meiling Road, Nanchang 330004, China
| | - Jianping Gong
- Division of Pharmaceutics, Jiangxi University of Traditional Chinese Medicine, No. 1688 Meiling Road, Nanchang 330004, China
| | - Zhiqiang Yu
- School of Pharmaceutical Sciences, Southern Medical University, No. 1023, Shatai South Road, Guangzhou 510515, China
| |
Collapse
|
31
|
Luo M, Groaz E, Snoeck R, Andrei G, Herdewijn P. Amidate Prodrugs of O-2-Alkylated Pyrimidine Acyclic Nucleosides Display Potent Anti-Herpesvirus Activity. ACS Med Chem Lett 2020; 11:1410-1415. [PMID: 32676147 DOI: 10.1021/acsmedchemlett.0c00090] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2020] [Accepted: 06/19/2020] [Indexed: 12/14/2022] Open
Abstract
Three series of amidate prodrugs of O-2-alkylated acyclic nucleosides of the 3-fluoro-2-(phosphonomethoxy)propyl (FPMP), cyclic 3-hydroxy-2-(phosphonomethoxypropyl) (cHPMP), and 2-(phosphonomethoxypropyl) (PMP)-type featuring cytosine and 5-fluorocytosine as nucleobases were readily synthesized. Both the aspartic acid ester and valine ester prodrugs of (R)-O-2-alkylated FPMPC exhibited potent anti-HCMV and VZV activity in the micromolar range. In addition, the valine ester prodrugs of 5-fluorocytosine (R)-O-2-alkylated FPMP and (R)-O-2-alkylated cHPMPC showed inhibitory activity at molar concentrations against these viruses.
Collapse
Affiliation(s)
- Min Luo
- Medicinal Chemistry, Rega Institute for Medical Research, KU Leuven, Herestraat 49 box 1041, 3000 Leuven, Belgium
| | - Elisabetta Groaz
- Medicinal Chemistry, Rega Institute for Medical Research, KU Leuven, Herestraat 49 box 1041, 3000 Leuven, Belgium
| | - Robert Snoeck
- Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, KU Leuven, Herestraat 49 box 1043, 3000 Leuven, Belgium
| | - Graciela Andrei
- Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, KU Leuven, Herestraat 49 box 1043, 3000 Leuven, Belgium
| | - Piet Herdewijn
- Medicinal Chemistry, Rega Institute for Medical Research, KU Leuven, Herestraat 49 box 1041, 3000 Leuven, Belgium
| |
Collapse
|
32
|
Procházková E, Filo J, Cigáň M, Baszczyňski O. Sterically-Controlled Self-Immolation in Phosphoramidate Linkers Triggered by Light. European J Org Chem 2020. [DOI: 10.1002/ejoc.201901882] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Eliška Procházková
- Institute of Organic Chemistry and Biochemistry; The Czech Academy of Sciences, Flemingovo nám. 542/2; 116 10 Prague Czech Republic
| | - Juraj Filo
- Institute of Chemistry, Faculty of Natural Sciences; Comenius University, Ilkovičova 6; Bratislava 842 15 Slovakia
| | - Marek Cigáň
- Institute of Chemistry, Faculty of Natural Sciences; Comenius University, Ilkovičova 6; Bratislava 842 15 Slovakia
| | - Ondřej Baszczyňski
- Department of Organic Chemistry, Faculty of Science; Charles University, Hlavova 2030/8; 128 43 Prague Czech Republic
| |
Collapse
|
33
|
Cavaliere A, Probst KC, Paisey SJ, Marshall C, Dheere AKH, Aigbirhio F, McGuigan C, Westwell AD. Radiosynthesis of [ 18F]-Labelled Pro-Nucleotides (ProTides). Molecules 2020; 25:E704. [PMID: 32041321 PMCID: PMC7037993 DOI: 10.3390/molecules25030704] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2019] [Revised: 01/25/2020] [Accepted: 02/01/2020] [Indexed: 12/31/2022] Open
Abstract
Phosphoramidate pro-nucleotides (ProTides) have revolutionized the field of anti-viral and anti-cancer nucleoside therapy, overcoming the major limitations of nucleoside therapies and achieving clinical and commercial success. Despite the translation of ProTide technology into the clinic, there remain unresolved in vivo pharmacokinetic and pharmacodynamic questions. Positron Emission Tomography (PET) imaging using [18F]-labelled model ProTides could directly address key mechanistic questions and predict response to ProTide therapy. Here we report the first radiochemical synthesis of [18F]ProTides as novel probes for PET imaging. As a proof of concept, two chemically distinct radiolabelled ProTides have been synthesized as models of 3'- and 2'-fluorinated ProTides following different radiosynthetic approaches. The 3'-[18F]FLT ProTide was obtained via a late stage [18F]fluorination in radiochemical yields (RCY) of 15-30% (n = 5, decay-corrected from end of bombardment (EoB)), with high radiochemical purities (97%) and molar activities of 56 GBq/μmol (total synthesis time of 130 min.). The 2'-[18F]FIAU ProTide was obtained via an early stage [18F]fluorination approach with an RCY of 1-5% (n = 7, decay-corrected from EoB), with high radiochemical purities (98%) and molar activities of 53 GBq/μmol (total synthesis time of 240 min).
Collapse
Affiliation(s)
- Alessandra Cavaliere
- School of Pharmacy & Pharmaceutical Sciences, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff CF10 3NB, Wales, UK; (A.C.)
- Wales Research & Diagnostic Positron Emission Tomography Imaging Centre (PETIC), School of Medicine, Cardiff University, University Hospital of Wales, Heath Park, Cardiff CF14 4XN, Wales, UK; (K.C.P.); (S.J.P.); (C.M.)
| | - Katrin C. Probst
- Wales Research & Diagnostic Positron Emission Tomography Imaging Centre (PETIC), School of Medicine, Cardiff University, University Hospital of Wales, Heath Park, Cardiff CF14 4XN, Wales, UK; (K.C.P.); (S.J.P.); (C.M.)
| | - Stephen J. Paisey
- Wales Research & Diagnostic Positron Emission Tomography Imaging Centre (PETIC), School of Medicine, Cardiff University, University Hospital of Wales, Heath Park, Cardiff CF14 4XN, Wales, UK; (K.C.P.); (S.J.P.); (C.M.)
| | - Christopher Marshall
- Wales Research & Diagnostic Positron Emission Tomography Imaging Centre (PETIC), School of Medicine, Cardiff University, University Hospital of Wales, Heath Park, Cardiff CF14 4XN, Wales, UK; (K.C.P.); (S.J.P.); (C.M.)
| | - Abdul K. H. Dheere
- Wolfson Brain Imaging Centre and Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, UK; (A.K.H.D.); (F.A.)
| | - Franklin Aigbirhio
- Wolfson Brain Imaging Centre and Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, UK; (A.K.H.D.); (F.A.)
| | - Christopher McGuigan
- School of Pharmacy & Pharmaceutical Sciences, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff CF10 3NB, Wales, UK; (A.C.)
| | - Andrew D. Westwell
- School of Pharmacy & Pharmaceutical Sciences, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff CF10 3NB, Wales, UK; (A.C.)
| |
Collapse
|
34
|
Zhou X, Wang S, Zhu Y, Pan Y, Zhang L, Yang Z. Overcoming the delivery barrier of oligonucleotide drugs and enhancing nucleoside drug efficiency: The use of nucleolipids. Med Res Rev 2019; 40:1178-1199. [PMID: 31820472 DOI: 10.1002/med.21652] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2019] [Revised: 11/15/2019] [Accepted: 11/19/2019] [Indexed: 12/13/2022]
Abstract
With the rapid development of synthetic technology and biological technology, many nucleic acid-based drugs have entered the clinical trials. However, their inherent disabilities in actively and efficiently penetrating cell membranes still severely restrict their further application. The main drawback of cationic lipids, which have been widely used as nonviral vectors of nucleic acids, is their high cytotoxicity. A series of nucleoside-based or nucleotide-based nucleolipids have been reported in recent years, due to their oligonucleotide delivery capacity and low toxicity in comparison with cationic lipids. Lipophilic prodrugs of nucleoside analogs have extremely similar structures with nucleolipid vectors and are thus helpful for improving the transmembrane ability. This review introduces the progress of nucleolipids and provides new strategies for improving the delivery efficiency of nucleic acid-based drugs, as well as lipophilic prodrugs of nucleosides or nucleotides for antiviral or anticancer therapies.
Collapse
Affiliation(s)
- Xinyang Zhou
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, Haidian, China
| | - Shuhe Wang
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, Haidian, China
| | - Yuejie Zhu
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, Haidian, China
| | - Yufei Pan
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, Haidian, China
| | - Lihe Zhang
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, Haidian, China
| | - Zhenjun Yang
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, Haidian, China
| |
Collapse
|
35
|
Baraniak D, Ruszkowski P, Baranowski D, Framski G, Boryski J. Nucleoside dimers analogs containing floxuridine and thymidine with unnatural linker groups: synthesis and cancer line studies. Part III. NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS 2019; 38:980-1005. [PMID: 31380708 DOI: 10.1080/15257770.2019.1641206] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Two series of novel fluorinated nucleosides dimers with an unnatural 1,2,3-triazole linkage were synthesized. The obtained molecules were prepared using "click" chemistry approach based on copper(I) catalyzed Huisgen azide-alkyne cycloaddition. It was performed between 3'- and 5'-azido-nucleosides as the azide components, and the 3'-O- and 5'-O-propargyl-nucleosides as the alkyne components. Based on analysis of the 3 JHH, 3 JH1'C2 and 3 JH1'C6 we estimated conformational preferences of sugar part and orientation around glycosidic bond. All described nucleosides dimers analogs were characterized by spectroscopic methods and evaluated for their in vitro cytotoxicity in three human cancer cell lines: cervical (HeLa), oral (KB) and breast (MCF-7).
Collapse
Affiliation(s)
- Dagmara Baraniak
- Institute of Bioorganic Chemistry, Polish Academy of Sciences , Poznań , Poland
| | - Piotr Ruszkowski
- Department of Pharmacology, Faculty of Pharmacy, Poznań University of Medical Sciences , Poznań , Poland
| | - Daniel Baranowski
- Institute of Bioorganic Chemistry, Polish Academy of Sciences , Poznań , Poland
| | - Grzegorz Framski
- Institute of Bioorganic Chemistry, Polish Academy of Sciences , Poznań , Poland
| | - Jerzy Boryski
- Institute of Bioorganic Chemistry, Polish Academy of Sciences , Poznań , Poland
| |
Collapse
|
36
|
Xu X, Chu Z, Xia C. Transition-metal free oxidative C-H etherification of acylanilines with alcohols through a radical pathway. Org Biomol Chem 2019; 17:6346-6350. [PMID: 31210244 DOI: 10.1039/c9ob01224a] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A transition metal free approach for the synthesis of methyl/ethyl aryl ether via oxidative C-H etherification of acylanilines with alcohols has been developed. Various acylanilines are compatible under standard conditions, giving the corresponding products in moderate to good yields. This strategy avoids transition-metal catalyst and excessive alcohol, providing a simple and reliable alternative method for the synthesis of methyl/ethyl aryl ether. Control experiments reveal that a radical mechanism is involved in this transformation.
Collapse
Affiliation(s)
- Xiaobo Xu
- Shanghai Synmedia Chemical Co., Ltd, Shanghai 201201, China and Pharmacy College, Shandong First Medical University & Shandong Academy of Medical Sciences, Taian 271000, China.
| | - Zhengzhou Chu
- Shanghai Synmedia Chemical Co., Ltd, Shanghai 201201, China
| | - Chengcai Xia
- Pharmacy College, Shandong First Medical University & Shandong Academy of Medical Sciences, Taian 271000, China.
| |
Collapse
|
37
|
Heidel KM, Dowd CS. Phosphonate prodrugs: an overview and recent advances. Future Med Chem 2019; 11:1625-1643. [PMID: 31469328 PMCID: PMC6722485 DOI: 10.4155/fmc-2018-0591] [Citation(s) in RCA: 52] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2018] [Accepted: 03/29/2019] [Indexed: 01/04/2023] Open
Abstract
Phosphonates, often used as isosteric replacements for phosphates, can provide important interactions with an enzyme. Due to their high charge at physiological pH, however, permeation into cells can be a challenge. Protecting phosphonates as prodrugs has shown promise in drug delivery. Thus, a variety of structures and cleavage/activation mechanisms exist, enabling release of the active compound. This review describes the structural diversity of these pro-moieties, relevant cleavage mechanisms and recent advances in the design of phosphonate prodrugs.
Collapse
Affiliation(s)
- Kenneth M Heidel
- Department of Chemistry, George Washington University, Washington, DC 20052, USA
| | - Cynthia S Dowd
- Department of Chemistry, George Washington University, Washington, DC 20052, USA
| |
Collapse
|
38
|
Baraniak D, Baranowski D, Ruszkowski P, Boryski J. Nucleoside dimers analogues with a 1,2,3-triazole linkage: conjugation of floxuridine and thymidine provides novel tools for cancer treatment. Part II. NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS 2019; 38:807-835. [PMID: 31177919 DOI: 10.1080/15257770.2019.1610891] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The fluorinated nucleoside dimers with a 1,2,3-triazole linkage are novel compounds within the field of bioorganic chemistry. We report on the synthesis and properties of two groups of nucleoside dimers analogs possessing a different arrangement of the 1,4-disubstituted 1,2,3-triazole linkage. Based on analysis of the 3JHH, 3JH1'C2, and 3JH1'C6 we estimated conformational preferences of sugar part and orientation around glycosidic bond. These compounds show moderate anticancer activity, with cytostatic studies in three different cancer cell lines.
Collapse
Affiliation(s)
- Dagmara Baraniak
- Institute of Bioorganic Chemistry, Polish Academy of Sciences , Poznań , Poland
| | - Daniel Baranowski
- Institute of Bioorganic Chemistry, Polish Academy of Sciences , Poznań , Poland
| | - Piotr Ruszkowski
- Department of Pharmacology, Faculty of Pharmacy, Poznań University of Medical Sciences , Poznań , Poland
| | - Jerzy Boryski
- Institute of Bioorganic Chemistry, Polish Academy of Sciences , Poznań , Poland
| |
Collapse
|
39
|
Kleczewska N, Ruszkowski P, Singh A, Trznadel R, Celewicz L. Synthesis and anticancer activity of 3'-[4-fluoroaryl-(1,2,3-triazol-1-yl)]-3'-deoxythymidine analogs and their phosphoramidates. NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS 2019; 38:605-641. [PMID: 30968733 DOI: 10.1080/15257770.2019.1594282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
A series of novel 4-chlorophenyl N-alkyl phosphoramidates of 3'-[4-fluoroaryl-(1,2,3-triazol-1-yl)]-3'-deoxythymidines (20-49) was synthesized by means of phosphorylation of 3'-[4-aryl-(1,2,3-triazol-1-yl)]-3'-deoxythymidines (7-11) with 4-chlorophenyl phosphoroditriazolide (14), followed by a reaction with the appropriate amine. The synthesized compounds 7-11 and 20-49 were evaluated along with four known anticancer compounds for their cytotoxic activity in human cancer cell lines: cervical (HeLa), nasopharyngeal (KB), breast (MCF-7), osteosarcoma (143B) (only selected compounds 20, 24, 28, 32-36, 38, 40, 46) and normal human dermal fibroblast cell line (HDF) using the sulforhodamine B (SRB) assay. Among 3'-[4-aryl-(1,2,3-triazol-1-yl)]-3'-deoxythymidines (7-11) the highest activity in all the investigated cancer cells was displayed by 3'-[4-(3-fluorophenyl)-(1,2,3-triazol-1-yl)]-3'-deoxythymidine (9) (IC50 in the range of 2.58-3.61 μM) and its activity was higher than that of cytarabine. Among phosphoramidates 20-49 the highest activity was demonstrated by N-n-propyl phosphoramidate of 3'-[4-(3-fluorophenyl)-(1,2,3-triazol-1-yl)]-3'-deoxythymidine (35) in all the cancer cells (IC50 in the range of 0.97-1.94 μM). Also N-ethyl phosphoramidate of 3'-[4-(3-fluorophenyl)-(1,2,3-triazol-1-yl)]-3'-deoxythymidine (33) exhibited good activity in all the used cell lines (IC50 in the range of 4.79-4.96 μM).
Collapse
Affiliation(s)
| | - Piotr Ruszkowski
- b Department of Pharmacology , Poznań University of Medical Sciences , Poznań , Poland
| | - Aleksandra Singh
- a Faculty of Chemistry , Adam Mickiewicz University , Poznań , Poland
| | - Roksana Trznadel
- a Faculty of Chemistry , Adam Mickiewicz University , Poznań , Poland
| | - Lech Celewicz
- a Faculty of Chemistry , Adam Mickiewicz University , Poznań , Poland
| |
Collapse
|
40
|
Chen X, Xiao Z, Chu H, Wang B, Peng AY. Reinvestigation of the iodine-mediated phosphoramidation reaction of amines and P(OR) 3 and its synthetic applications. Org Biomol Chem 2019; 16:6783-6790. [PMID: 30198043 DOI: 10.1039/c8ob01840e] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A systematic study on the iodine-mediated phosphoramidation reaction of amines and trialkyl phosphites was conducted, which not only disclosed the factors affecting the reaction but also revealed that it could proceed smoothly in CH2Cl2 at room temperature in open air. Using this method, various phosphoramidates with different aliphatic amines and aromatic amines were synthesized in good to excellent yields. Our present investigation shows that this underused method is actually a mild, practical and general way to synthesize phosphoramidates and will have wide applications.
Collapse
Affiliation(s)
- Xunwei Chen
- School of Chemistry, Sun Yat-sen University, 135 Xingangxi Lu, Guangzhou, 510275, China.
| | | | | | | | | |
Collapse
|
41
|
Procházková E, Navrátil R, Janeba Z, Roithová J, Baszczyňski O. Reactive cyclic intermediates in the ProTide prodrugs activation: trapping the elusive pentavalent phosphorane. Org Biomol Chem 2019; 17:315-320. [PMID: 30543240 DOI: 10.1039/c8ob02870b] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Nucleotide prodrugs (ProTides) based on phosphate or phosphonate compounds are potent and successfully marketed antiviral drugs. Although their biological properties are well explored, experimental evidence on the mechanism of their activation pathway is still missing. In this study, we synthesized two ProTide analogues, which can be activated by UV light. Using 31P and 13C NMR spectroscopy with in situ irradiation, we followed the ProTide activation pathway in various solvents, and we detected the first proposed intermediate and the monoamidate product. Furthermore, we used mass spectrometry (MS) coupled with infrared spectroscopy in the gas phase to detect and to characterize the elusive cyclic pentavalent phosphorane and cyclic acyl phosphoramidate intermediates. Our combined NMR and MS data provided the first experimental evidence of the cyclic intermediates in the activation pathway of ProTide prodrugs.
Collapse
Affiliation(s)
- Eliška Procházková
- Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo nám. 2, 166 10 Prague 6, Czech Republic.
| | | | | | | | | |
Collapse
|
42
|
Shen J, Xu J, Cai H, Shen C, Zhang P. Platinum(ii)-catalyzed selective para C-H alkoxylation of arylamines through a coordinating activation strategy. Org Biomol Chem 2019; 17:490-497. [PMID: 30566159 DOI: 10.1039/c8ob02942c] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
A highly efficient method to selectively install alkoxy onto the para position of arylamines via a coordinating activation strategy has been reported. Various substrates are compatible, providing the corresponding products in good to excellent yields. This strategy gives an efficient and practical solution for the synthesis of unsymmetrical aryl ethers. A free radical pathway mechanism is advised for transformation.
Collapse
Affiliation(s)
- Jiabin Shen
- College of Material, Chemistry and Chemical Engineering, Hangzhou Normal University, Hangzhou 310036, China.
| | | | | | | | | |
Collapse
|
43
|
Slusarczyk M, Ferrari V, Serpi M, Gönczy B, Balzarini J, McGuigan C. Symmetrical Diamidates as a Class of Phosphate Prodrugs to Deliver the 5′‐Monophosphate Forms of Anticancer Nucleoside Analogues. ChemMedChem 2018; 13:2305-2316. [DOI: 10.1002/cmdc.201800504] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2018] [Indexed: 11/05/2022]
Affiliation(s)
- Magdalena Slusarczyk
- School of Pharmacy and Pharmaceutical SciencesCardiff University King Edward VII Avenue Cardiff CF10 3NB UK
| | - Valentina Ferrari
- School of Pharmacy and Pharmaceutical SciencesCardiff University King Edward VII Avenue Cardiff CF10 3NB UK
| | - Michaela Serpi
- School of Pharmacy and Pharmaceutical SciencesCardiff University King Edward VII Avenue Cardiff CF10 3NB UK
| | - Blanka Gönczy
- School of Pharmacy and Pharmaceutical SciencesCardiff University King Edward VII Avenue Cardiff CF10 3NB UK
| | - Jan Balzarini
- Laboratory of Virology and ChemotherapyRega Institute for Medical Research Herestraat 49 3000 Leuven Belgium
| | - Christopher McGuigan
- School of Pharmacy and Pharmaceutical SciencesCardiff University King Edward VII Avenue Cardiff CF10 3NB UK
| |
Collapse
|
44
|
Pileggi E, Serpi M, Pertusati F. Preparation of Pyrimidine Alkenyl Acyclic Nucleoside Phosphonoamidates. ACTA ACUST UNITED AC 2018; 74:e56. [DOI: 10.1002/cpnc.56] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Affiliation(s)
- Elisa Pileggi
- School of Pharmacy and Pharmaceutical Sciences, Cardiff University; Cardiff United Kingdom
| | - Michaela Serpi
- School of Pharmacy and Pharmaceutical Sciences, Cardiff University; Cardiff United Kingdom
| | - Fabrizio Pertusati
- School of Pharmacy and Pharmaceutical Sciences, Cardiff University; Cardiff United Kingdom
| |
Collapse
|
45
|
Pileggi E, Serpi M, Andrei G, Schols D, Snoeck R, Pertusati F. Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs. Bioorg Med Chem 2018; 26:3596-3609. [PMID: 29880251 PMCID: PMC7126595 DOI: 10.1016/j.bmc.2018.05.034] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2018] [Revised: 05/18/2018] [Accepted: 05/22/2018] [Indexed: 01/27/2023]
Abstract
The importance of phosphonoamidate prodrugs (ProTides) of acyclic nucleoside phosphonate (ANPs) is highlighted by the approval of Tenofovir Alafenamide Fumarate for the treatment of HIV and HBV infections. In the present paper we are reporting an expedient, one-pot, two-steps synthesis of allyl phosphonoamidates and diamidates that offers a time saving strategy when compared to literature methods. The use of these substrates in the cross metathesis reactions with alkenyl functionalised thymine and uracil nucleobases is reported. ANPs prodrugs synthesized via this methodology were evaluated for their antiviral activities against DNA and RNA viruses. It is anticipated that the use of 5,6,7,8-tetrahydro-1-napthyl as aryloxy moiety is capable to confer antiviral activity among a series of otherwise inactive uracil ProTides.
Collapse
Affiliation(s)
- Elisa Pileggi
- School of Pharmacy and Pharmaceutical Sciences, Redwood building, King Edwards VII Avenue, CF10 3NB Cardiff, Wales, United Kingdom
| | - Michaela Serpi
- School of Pharmacy and Pharmaceutical Sciences, Redwood building, King Edwards VII Avenue, CF10 3NB Cardiff, Wales, United Kingdom
| | - Graciela Andrei
- Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium
| | - Dominique Schols
- Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium
| | - Robert Snoeck
- Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium
| | - Fabrizio Pertusati
- School of Pharmacy and Pharmaceutical Sciences, Redwood building, King Edwards VII Avenue, CF10 3NB Cardiff, Wales, United Kingdom.
| |
Collapse
|
46
|
Luo M, Groaz E, De Jonghe S, Snoeck R, Andrei G, Herdewijn P. Amidate Prodrugs of Cyclic 9-( S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]adenine with Potent Anti-Herpesvirus Activity. ACS Med Chem Lett 2018; 9:381-385. [PMID: 29670705 DOI: 10.1021/acsmedchemlett.8b00079] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2018] [Accepted: 03/09/2018] [Indexed: 12/24/2022] Open
Abstract
A series of amidate prodrugs of cyclic 9-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine (cHPMPA) featuring different amino acid motifs were synthesized. All phosphonamidates derived from (S)-cHPMPA displayed a broad spectrum activity against herpesviruses with EC50 values in the low nanomolar range. A phosphonobisamidate prodrug of (S)-HPMPA also exhibited a remarkably potent antiviral activity. In addition, the leucine ester prodrug of (S)-cHPMPA and phosphonobisamidate valine ester prodrug of (S)-HPMPA proved stable in human plasma. These data warrant further development of cHPMPA prodrugs, especially against human cytomegalovirus (HCMV), for which there is a high need for treatment in transplant recipients.
Collapse
Affiliation(s)
- Min Luo
- Medicinal Chemistry, Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium
| | - Elisabetta Groaz
- Medicinal Chemistry, Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium
| | - Steven De Jonghe
- Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, KU Leuven, Herestraat 49 bus 1043, 3000 Leuven, Belgium
| | - Robert Snoeck
- Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, KU Leuven, Herestraat 49 bus 1043, 3000 Leuven, Belgium
| | - Graciela Andrei
- Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, KU Leuven, Herestraat 49 bus 1043, 3000 Leuven, Belgium
| | - Piet Herdewijn
- Medicinal Chemistry, Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium
| |
Collapse
|
47
|
Maiti M, Gao LJ, Huang C, Ptak RG, Murray MG, De Jonghe S, Herdewijn P. Bifunctional aryloxyphosphoramidate prodrugs of 2'-C-Me-uridine: synthesis and anti-HCV activity. Org Biomol Chem 2018; 14:8743-8757. [PMID: 27714209 DOI: 10.1039/c6ob01189f] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
In an attempt to identify novel nucleoside phosphoramidate analogues for improving the anti-HCV activity of 2'-C-Me-uridine, we have synthesized for the first time a series of l-glutamic acid, l-serine, l-threonine and l-tyrosine containing aryloxyphosphoramidate prodrugs of 2'-C-Me-uridine. Evaluation of their activity against HCV revealed that they displayed very potent anti-HCV activity, with EC50 values that are in the same range as of Sofosbuvir.
Collapse
Affiliation(s)
- Munmun Maiti
- KU Leuven, Rega Institute, Laboratory of Medicinal Chemistry, Minderbroedersstraat 10, 3000 Leuven, Belgium.
| | - Ling-Jie Gao
- KU Leuven, Rega Institute, Laboratory of Medicinal Chemistry, Minderbroedersstraat 10, 3000 Leuven, Belgium.
| | - Chunsheng Huang
- Southern Research, Infectious Disease Research, 431 Aviation Way, Frederick, MD 21701, USA
| | - Roger G Ptak
- Southern Research, Infectious Disease Research, 431 Aviation Way, Frederick, MD 21701, USA
| | - Michael G Murray
- Southern Research, Infectious Disease Research, 431 Aviation Way, Frederick, MD 21701, USA
| | - Steven De Jonghe
- KU Leuven, Rega Institute, Laboratory of Medicinal Chemistry, Minderbroedersstraat 10, 3000 Leuven, Belgium.
| | - Piet Herdewijn
- KU Leuven, Rega Institute, Laboratory of Medicinal Chemistry, Minderbroedersstraat 10, 3000 Leuven, Belgium.
| |
Collapse
|
48
|
Slusarczyk M, Serpi M, Pertusati F. Phosphoramidates and phosphonamidates (ProTides) with antiviral activity. Antivir Chem Chemother 2018; 26:2040206618775243. [PMID: 29792071 PMCID: PMC5971382 DOI: 10.1177/2040206618775243] [Citation(s) in RCA: 68] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2017] [Accepted: 04/09/2018] [Indexed: 12/15/2022] Open
Abstract
Following the first report on the nucleoside phosphoramidate (ProTide) prodrug approach in 1990 by Chris McGuigan, the extensive investigation of ProTide technology has begun in many laboratories. Designed with aim to overcome limitations and the key resistance mechanisms associated with nucleoside analogues used in the clinic (poor cellular uptake, poor conversion to the 5'-monophosphate form), the ProTide approach has been successfully applied to a vast number of nucleoside analogues with antiviral and anticancer activity. ProTides consist of a 5'-nucleoside monophosphate in which the two hydroxyl groups are masked with an amino acid ester and an aryloxy component which once in the cell is enzymatically metabolized to deliver free 5'-monophosphate, which is further transformed to the active 5'-triphosphate form of the nucleoside analogue. In this review, the seminal contribution of Chris McGuigan's research to this field is presented. His technology proved to be extremely successful in drug discovery and has led to two Food and Drug Administration-approved antiviral agents.
Collapse
Affiliation(s)
| | - Michaela Serpi
- School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, UK
| | - Fabrizio Pertusati
- School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, UK
| |
Collapse
|
49
|
Szymanska-Michalak A, Wawrzyniak D, Framski G, Stawinski J, Barciszewski J, Kraszewski A. New antiglioma zwitterionic pronucleotides with an FdUMP framework. Eur J Med Chem 2017; 144:682-691. [PMID: 29289891 DOI: 10.1016/j.ejmech.2017.12.070] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2017] [Revised: 11/24/2017] [Accepted: 12/18/2017] [Indexed: 01/07/2023]
Abstract
We have designed and synthesized new 5-fluoro-2'-deoxyuridine 5'-phosphate pronucleotides which can function as potential agents against the glioblastoma multiforme tumor. Their anti-malignant potency has been tested against T98G, U-118 MG, U-87 MG gliomas, HeLa, and Caco-2 cancer cell lines, using MRC-5 healthy cells as a reference. Five of the sixteen compounds (4c, 4f-i) exhibited significant anticancer potency and high selectivity indices (SI 12-66). It is likely that these zwitterionic pronucleotides may function in a similar manner to zwitterionic phospholipids, by inducing cell membrane charge disorder, making the cell permeable to bioactive agents. The most promising therapeutic pronucleotides 4c, 4f-h, have high intestinal-blood uptake potency (Caco-2 cell line), and may be considered as potential, orally administrated, anticancer drugs.
Collapse
Affiliation(s)
| | - Dariusz Wawrzyniak
- Institute of Bioorganic Chemistry, Polish Academy of Sciences, Noskowskiego 12/14, 61-704, Poznan, Poland
| | - Grzegorz Framski
- Institute of Bioorganic Chemistry, Polish Academy of Sciences, Noskowskiego 12/14, 61-704, Poznan, Poland
| | - Jacek Stawinski
- Institute of Bioorganic Chemistry, Polish Academy of Sciences, Noskowskiego 12/14, 61-704, Poznan, Poland
| | - Jan Barciszewski
- Institute of Bioorganic Chemistry, Polish Academy of Sciences, Noskowskiego 12/14, 61-704, Poznan, Poland
| | - Adam Kraszewski
- Institute of Bioorganic Chemistry, Polish Academy of Sciences, Noskowskiego 12/14, 61-704, Poznan, Poland.
| |
Collapse
|
50
|
Slusarczyk M, Ferla S, Brancale A, McGuigan C. Synthesis and biological evaluation of 6-substituted-5-fluorouridine ProTides. Bioorg Med Chem 2017; 26:551-565. [PMID: 29277307 DOI: 10.1016/j.bmc.2017.11.037] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2017] [Revised: 11/21/2017] [Accepted: 11/23/2017] [Indexed: 11/29/2022]
Abstract
A new family of thirteen phosphoramidate prodrugs (ProTides) of different 6-substituted-5-fluorouridine nucleoside analogues were synthesized and evaluated as potential anticancer agents. In addition, antiviral activity against Chikungunya (CHIKV) virus was evaluated using a cytopathic effect inhibition assay. Although a carboxypeptidase Y assay supported a putative mechanism of activation of ProTides built on 5-fluorouridine with such C6-modifications, the Hint docking studies revealed a compromised substrate-activity for the Hint phosphoramidase-type enzyme that is likely responsible for phosphoramidate bioactivation through P-N bond cleavage and free nucleoside 5'-monophosphate delivery. Our observations may support and explain to some extent the poor in vitro biological activity generally demonstrated by the series of 6-substituted-5-fluorouridine phosphoramidates (ProTides) and will be of guidance for the design of novel phosphoramidate prodrugs.
Collapse
Affiliation(s)
- Magdalena Slusarczyk
- School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, King Edward VII Avenue, Cardiff CF10 3NB, UK.
| | - Salvatore Ferla
- School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, King Edward VII Avenue, Cardiff CF10 3NB, UK
| | - Andrea Brancale
- School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, King Edward VII Avenue, Cardiff CF10 3NB, UK
| | - Christopher McGuigan
- School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, King Edward VII Avenue, Cardiff CF10 3NB, UK
| |
Collapse
|